287472-25-7

Upstream product

• 10070-92-5 pyrimidine-5-carbaldehyde 
• 287472-24-6 hydroxy(pyrimidin-5-yl)acetonitrile 

Downstream Products

• 146422-56-2 1-Triphenylmethyl-5(3(1-n-heptanoxy)-1,2,5-thiadiazol-4-yl)-1,4,5,6-tetrahydropyrimidine HCl 
• 287472-35-9 5-[4-(4-methyl-benzyloxy)-[1,2,5]thiadiazol-3-yl]-pyrimidine 
• 287472-36-0 5-[4-(4-chloro-benzyloxy)-[1,2,5]thiadiazol-3-yl]-pyrimidine 
• 287472-34-8 5-(4-benzyloxy-[1,2,5]thiadiazol-3-yl)-pyrimidine 
• 287472-28-0 5-(4-ethoxy-[1,2,5]thiadiazol-3-yl)-pyrimidine 
• 647860-11-5 5-[4-(4-chloro-benzylsulfanyl)-[1,2,5]thiadiazol-3-yl]-pyrimidine 
• 647860-10-4 5-[4-(4-methyl-benzylsulfanyl)-[1,2,5]thiadiazol-3-yl]-pyrimidine 
• 647860-09-1 5-(4-benzylsulfanyl-[1,2,5]thiadiazol-3-yl)-pyrimidine 

Relevant academic research and scientific papers

Synthesis of 5-(4-alkylsulfanyl-[1,2,5]thiadiazol-3-yl)-3-methyl-1,2,3, 4-tetrahydropyrimidine oxalate salts and their evaluation as muscarinic receptor agonists

The synthesis and biological test of 5-(4-alkylsulfanyl-[1,2,5]thiadiazol-3-yl)-3-methyl-1,2,3, 4-tetrahydropyrimidine oxalate salts 7 as muscarinic receptor agonists are described. The key intermediate 4 was obtained by a modified Strecker reaction and cyclization, and the 3-methyl-1,2,3,4-tetrahydropyrimidines were obtained by subsequent substitution, quarternization, and reduction. The final products 7 were obtained as oxalic acid salts. The prepared compounds were examined in vitro for their binding affinities to the cloned human muscarinic receptor by the [3H]-NMS binding assay.

Synthesis of 5-(4-alkoxy-[1,2,5]thiadiazol-3-yl)-3-methyl-1,2,3,4- tetrahydropyrimidine oxalate salts and their evaluation as muscarinic receptor agonists

The synthesis and biological testing of 5-(4-alkoxy-[1,2,5]thiadiazol-3- yl)-3-methyl-1,2,3,4-tetrahydropyrimidine oxalate salts 8 as muscarinic receptor agonists are described. The key intermediate 4 was obtained by modified Strecker reaction and cyclization of starting material 1. Subsequent alkoxy substitution, quaternization, and reduction afforded 7. For the sake of purity and stability of the final products 8, the 3-methyl-1,2,3,4- tetrahydropyrimidines were obtained as oxalic acid salts. All final compounds were examined in vitro for their binding affinities to the cloned human muscarinic receptor by the [3H]-NMS binding assay.

Muscarinic agonists

Substituted 1,4,5,6 -tetrahydropyrimidine compositions, substituted 1,2,3,6-tetrahydropyrimidine compositions and substituted 3,4,5,6-tetrahydropyridine compositions are disclosed. They are useful for stimulating muscarinic receptors including, for example, treating the symptoms of cognitive disorders, especially impared memory, which are associated with decreased acetylcholine synthesis and cholinergic cell degeneration.